ARCHIVES

Phase IIb Trial of CRLX101 Fails Overall Survival Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 3 | March 29, 2013

Download PDF Visit The Full Archive

Related Articles

ODAC Rejects Amsacrine NDA, Renews Idarubicin

September 14, 1990

Workshop Calls For Improved Surgical Oncology Training Programs

December 2, 1983

Antibody Targeting PD-L1 Shows Fast Tumor Shrinkage

May 31, 2013

United Approach With Other Health Advocates Needed To Increase Cancer Dollars, Royboal Says

February 10, 1978

In Brief: Susumu Tonegawa To Receive Bristol-Myers Award; Mark Green Named Director Of UCSD Cancer Center

March 7, 1986

Wyngaarden Recommendation On New Director Due Nov. 1o; Five Staff Members Nominated

November 4, 1988